Africa Fighting Malaria, Washington, DC, USA.
Malar J. 2009 Dec 22;8:305. doi: 10.1186/1475-2875-8-305.
In an effort to increase competition and decrease price, the Global Fund to Fight AIDS, Tuberculosis and Malaria recently began asking some grant recipients to use international competitive bidding processes for certain drug purchases. Unfortunately, for countries like Kenya, this request has caused more harm than good. After awarding the tender for its annual supply of the anti-malarial artemether-lumefantrine to the lowest bidder, Ajanta Pharma, Kenya experienced wide stock-outs in part due to the company's inability to supply the order in full and on time. Similar problems could arise in Uganda. Despite Kenya's experience, Uganda has awarded its next tender for artemether-lumefantrine to Ajanta Pharma. Uganda is already facing wide stock-outs and risks exacerbating an already dire situation the longer it takes to fulfil the procurement contract. A tender process based primarily on price cannot account for a company's ability to consistently supply sufficient product in time.
为了增加竞争并降低价格，全球抗击艾滋病、结核病和疟疾基金最近开始要求一些受赠国对某些药品采购采用国际竞争性招标程序。不幸的是，对于肯尼亚等国家来说，这一要求弊大于利。在将年度抗疟药青蒿琥酯-本芴醇的招标授予最低报价者 Ajanta Pharma 后，肯尼亚部分地区出现了严重的缺货现象，部分原因是该公司无法按时足额供应订单。类似的问题也可能出现在乌干达。尽管肯尼亚有此经验，乌干达还是将其下一个青蒿琥酯-本芴醇的招标授予了 Ajanta Pharma。肯尼亚已经面临严重缺货的情况，如果要完成采购合同，时间拖得越久，情况就会越恶化。一个主要基于价格的招标程序不能说明一个公司是否有能力持续及时供应足够的产品。
